Abstract
The purpose of this study was to develop a solid nanoemulsion preconcentrate (NanOsorb) for poorly watersoluble drug sertraline (SRT). The liquid SNEDDS consisted of LabrafilM 2125 CS and Maisine 35-1 in 1:1 ratio as oil phase, Tween 80 as surfactant, Lauroglycol 90 as co-surfactant and active constituent sertraline free base. SRT free base, rather than commercially available hydrochloride salts (SRT.HCl) was used due to its much higher solubility in lipidic solvents. The NanOsorb formulation was prepared by adsorbing the liquid SNEDDS on different solid adsorbents. Reconstitution properties of both liquid and solid formulation demonstrate insignificant difference (p > 0.05) in the globule size. External morphology and physical state of sertraline in NanOsorb formulation were examined by TEM, DSC, and X-ray powder diffraction. In vitro release profile of NanOsorb was found to be significant (p < 0.001) in comparison to the plane SRT in pH 1.2, 4.5 and 6.8 buffers. Formulation was subjected to stability studies as per International Conference on Harmonization (ICH) guidelines and was found to be stable. No significant variations were observed in the formulation over a period of 3 months at accelerated conditions. Results deduced that NanOsorb formulation may provide an improvement in dissolution profile of poorly water-soluble drugs in the form of solid dosage form.
Keywords: Sertraline, oral delivery, solid nanoemulsion preconcentrate (NanOsorb), solid carrier, stability, SEDDS, SNEDDS, Pseudoternary Phase, co-surfactant, pseudo-ternary phase, Globule, Reconstitution, nanoemulsions, phosphotungstic acid, Diffraction
Drug Delivery Letters
Title:Solid Nanoemulsion Preconcentrate (NanOsorb) for Oral Delivery of Sertraline: Development and Characterization
Volume: 2 Issue: 4
Author(s): Md. Akhlaquer Rahman, Zeenat Iqbal and Arshad Hussain
Affiliation:
Keywords: Sertraline, oral delivery, solid nanoemulsion preconcentrate (NanOsorb), solid carrier, stability, SEDDS, SNEDDS, Pseudoternary Phase, co-surfactant, pseudo-ternary phase, Globule, Reconstitution, nanoemulsions, phosphotungstic acid, Diffraction
Abstract: The purpose of this study was to develop a solid nanoemulsion preconcentrate (NanOsorb) for poorly watersoluble drug sertraline (SRT). The liquid SNEDDS consisted of LabrafilM 2125 CS and Maisine 35-1 in 1:1 ratio as oil phase, Tween 80 as surfactant, Lauroglycol 90 as co-surfactant and active constituent sertraline free base. SRT free base, rather than commercially available hydrochloride salts (SRT.HCl) was used due to its much higher solubility in lipidic solvents. The NanOsorb formulation was prepared by adsorbing the liquid SNEDDS on different solid adsorbents. Reconstitution properties of both liquid and solid formulation demonstrate insignificant difference (p > 0.05) in the globule size. External morphology and physical state of sertraline in NanOsorb formulation were examined by TEM, DSC, and X-ray powder diffraction. In vitro release profile of NanOsorb was found to be significant (p < 0.001) in comparison to the plane SRT in pH 1.2, 4.5 and 6.8 buffers. Formulation was subjected to stability studies as per International Conference on Harmonization (ICH) guidelines and was found to be stable. No significant variations were observed in the formulation over a period of 3 months at accelerated conditions. Results deduced that NanOsorb formulation may provide an improvement in dissolution profile of poorly water-soluble drugs in the form of solid dosage form.
Export Options
About this article
Cite this article as:
Akhlaquer Rahman Md., Iqbal Zeenat and Hussain Arshad, Solid Nanoemulsion Preconcentrate (NanOsorb) for Oral Delivery of Sertraline: Development and Characterization, Drug Delivery Letters 2012; 2 (4) . https://dx.doi.org/10.2174/2210304x11202040001
DOI https://dx.doi.org/10.2174/2210304x11202040001 |
Print ISSN 2210-3031 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-304X |
Call for Papers in Thematic Issues
Nanomaterial Assisted Targeted Therapies for Chronic Disorders- Preclinical to Clinical Outcomes
In recent years, the integration of nanomaterials into therapeutic strategies has emerged as a promising avenue in the pursuit of more effective treatments for chronic disorders. This dynamic field, explored in the context of "Nanomaterial Assisted Targeted Therapies for Chronic Disorders - Preclinical to Clinical Outcomes," seeks to bridge the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Testosterone Deficiency Syndrome: Cellular and Molecular Mechanism of Action
Current Aging Science The Latent Structure of Mental Disorders: A Taxometric Update on the Categorical vs Dimensional Debate
Current Psychiatry Reviews Silymarin Extends Lifespan and Reduces Proteotoxicity in C. elegans Alzheimer’s Model
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member
Current Alzheimer Research Systematic Review of the Reliability and Validity of Translated Interview Measures of Psychotic Symptoms
Current Psychiatry Reviews Is Nicotine Protective Against Parkinson´s Disease? An Experimental Analysis
CNS & Neurological Disorders - Drug Targets Milk Fat Globule Epidermal Growth Factor VIII Signaling in Arterial Wall Remodeling
Current Vascular Pharmacology Intercalation of Erlotinib and Pemetrexed in the Treatment of Non-Small Cell Lung Cancer
Current Drug Targets Synthesis of Novel 8-alkylamino-5, 6-dihydro-4H-benzo[f] [1,2,4]triazolo [4,3-a]azepines as Anticonvulsant Agents
CNS & Neurological Disorders - Drug Targets Combined Effect of Parthenolide and Various Anti-cancer Drugs or Anticancer Candidate Substances on Malignant Cells in vitro and in vivo
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: Perinatal Stem Cells Patents and Applications: Regenerative Medicine, Tissue Repair, Immune Modulation)
Recent Patents on Regenerative Medicine Matter of Life and Death: the Pharmacological Approaches Targeting Apoptosis in Brain Diseases
Current Pharmaceutical Design Recent Advances in Perioperative Anesthetic Management Update in the Perioperative Support of Patients with Septic Shock and the Effect on Outcomes
Current Pharmaceutical Design The Control of Dopamine Neuron Development, Function and Survival: Insights From Transgenic Mice and The Relevance to Human Disease
Current Medicinal Chemistry Metabolism of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy: A Review of the Literature
Current Drug Metabolism Jatrorrhizine Protects Against Okadaic Acid Induced Oxidative Toxicity Through Inhibiting the Mitogen-Activated Protein Kinases Pathways in HT22 Hippocampal Neurons
CNS & Neurological Disorders - Drug Targets Induction of Cellular Oxidative Stress by the β-amyloid Peptide Involved in Alzheimers disease
Protein & Peptide Letters Epigenetic Modifications in Acute Lymphoblastic Leukemia: From Cellular Mechanisms to Therapeutics
Current Gene Therapy Protocatechuic Acid and Human Disease Prevention: Biological Activities and Molecular Mechanisms
Current Medicinal Chemistry Glycine Site Modulators and Glycine Transporter-1 Inhibitors as Novel Therapeutic Targets for the Treatment of Schizophrenia
Current Neuropharmacology